Impact of hormone therapy on quality of life after menopause

Menopause

Volumn 20, Issue 10, 2013, Pages 1098-1105

  Utian, Wulf H ^a,b,c   Woods, Nancy Fugate ^d  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c RMR Inc   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hormone therapy; Menopause; Quality of life; Validated quality of life instruments

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE;

CLIMACTERIUM; CLINICAL PRACTICE; HEALTH CARE; HORMONAL THERAPY; MEDICAL LITERATURE; MEDICAL RESEARCH; MENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; VALIDATION PROCESS; WELLBEING;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; POSTMENOPAUSE; PROGESTINS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; WOMEN'S HEALTH;

EID: 84885175124     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e318298debe     Document Type: Review

References (32)

1. Utian WH, Janata JJ, Kingsberg SA, et al. Determinants and quantification of quality of life after the menopause. The Utian Menopause Quality of Life Score. In: Aso T, eds. The Menopause at the Millennium. Carnforth, England: Parthenon Publishing, 2000: 141-144.
2. Utian WH. Impact of osteoporosis on quality of life and quality of life on osteoporosis: rationale and methodology for accurate assessment. In: Genazzani AR, ed. Postmenopausal Osteoporosis. New York, NY: Taylor and Francis, 2006: 11-15.
3. Avis N, Assmann S, Kravitz H, Ganz P, Ory M. Quality of life in diverse groups of midlife women: assessing the influence of menopause, health status, and psychosocial and demographic factors. Qual Life Res 2004;13: 933-946.
4. WHO Division of Mental Health. WHO-QOL Study Protocol. The Development of the World Health Organization Quality of Life Assessment Instrument (MNG/PSF/93). Geneva, Switzerland: WHO, 1993.
5. Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res 1976;20: 425-430.
6. Hunter M. The Women's Health Questionnaire (WHQ): a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7: 45-54.
7. Ware JJ, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), 1: conceptual framework and item selection. Med Care 1992;30: 473-483.
8. Hilditch JR, Lewis J, Peter A, et al. A Menopause-Specific Quality of Life questionnaire: development and psychometric qualities. Maturitas 1996;24: 161-175.
9. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. Maturitas 2005;50: 209-221.
10. Utian WH, Janata JJ, Kingsberg SA, Schluchter MS, Hamilton JC. The Utian Quality of Life (UQOL) Scale: development and validation of an instrument to quantify quality of life through and beyond menopause. Menopause 2002;9: 402-409.
11. Schneider HPG, MacLennan AH, Feeny D. Assessment of health-related quality of life in menopause and aging. Climacteric 2008;11: 93-107.
12. Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. Menopause 2009;16: 860-869.
13. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122: 42.e2-52.e2.
14. Utian WH. Application of cost effectiveness analysis to post-menopausal estrogen therapy. Front Horm Res 1977;5: 26-39.
15. Greene JG. Measuring the symptoms dimension of quality of life in general and menopause-specific scales and their subscale structure. In Schneider HPG, ed. Hormone Replacement Therapy and Quality of Life. Lancaster, England: Parthenon Publishing, 2002: 35-43.
16. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA 2002;287: 591-597.
17. Hays J, Ockene JK, Brunner RL, et al., for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348: 1839-1854.
18. Brunner RL, Gass M, Aragaki A, et al., for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized clinical trial. Arch Intern Med 2005;165: 1976-1986.
19. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12: 716-727.
20. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better healthrelated quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc 2005;11: 145-151.
21. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190.
22. Moriyama CK, Oneda B, Bernardo FR, et al. A randomized placebocontrolled trial of the effects of physical eercises and estrogen therapy on health-related quality of life in postmenopausal women. Menopause 2008;15: 613-618.
23. Battacharya SM, Jha A. Effects of transdermal estradiol gel and oral tibolone on health-related quality of life after surgical menopause. Int J Gynecol Obstet 2010: 110: 213-216.
24. Utian, W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar J. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63: 329-335.
25. Barnabei VM, Cochrane BB, Aragaki AK, et al., for the Women's Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105: 1063-1073.
26. Gleason C, Wharton W, Dowling M, et al. Kronos Early Prevention Study-Cognitive and Affective substudy (KEEPS-CA): menopausal hormone therapy effects on mood, quality of life and memory complaints [Abstract]. Menopause 2012;19: 1402.
27. Kind P. The EuroQoL instrument: an index of health-related quality of life. In Spilker B, ed. QOL and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996: 191-201.
28. Hunter M. The Women's Health Questionnaire (WHQ): the development, standardization and application of a measure of mid-aged women's emotional and physical health. Qual Life Res 2000;9: 733-738.
29. Perz JM. Development of the menopause symptom list. A factor analytic study of menopause associated symptoms. Womens Health 1997;25: 53-69.
30. Schneider HPG, Heinemann LAJ, Rosemeier HP, et al. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 2000;3: 50-58.
31. Chen P, Chao H, Chou K, et al. The Chinese Utian Quality of Life Scale for women around menopause: translation and psychometric testing. Menopause 2012;19: 438-447.
32. Pimenta F, Leal I, Maroco J, Rosa B, Utian WH, Adaptation of the Utian Quality of Life Scale to Portuguese using a community sample of Portuguese women in premenopause, perimenopause, and postmenopause. Menopause 2013;20: 532-539.